LON:GDRGenedrive Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genedrive PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 165 +0.50 (+0.30 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range 160.55Now: GBX 165▼ 215.5650-Day Range 23.50MA: GBX 101.25▼ 206.7552-Week Range 6.25Now: GBX 165▼ 302.60Volume2.11 million shsAverage Volume9,606 shsMarket Capitalization£57.54 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. It operates through three divisions: Preclinical Research Services, Pharmacogenomic Services, and Diagnostics. The Preclinical Research Services division provides pre-clinical testing services in the areas of oncology, oncology supportive care, inflammatory bowel disease, leukaemia, gastrointestinal disease, inflammation, skin care and wound healing, and rheumatoid arthritis. The Pharmacogenomic Services division offers molecular measures of biological processes. The Diagnostics division is involved in commercializing the Genedrive point of need molecular testing platform. It serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is based in Manchester, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genedrive. Previous Next 2.9 Community Rank Outperform VotesGenedrive has received 236 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenedrive has received 178 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenedrive has received 57.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genedrive and other stocks. Vote “Outperform” if you believe GDR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GDR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenedrive does not currently pay a dividend.Dividend GrowthGenedrive does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genedrive insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genedrive are expected to grow in the coming year, from GBX (8.70) to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genedrive is -10.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genedrive is -10.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.71 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:GDR Previous SymbolLON:EHP CUSIPN/A CIKN/A Webwww.genedriveplc.com Phone+44-161-9890245Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio3.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£1.50 million Price / Sales38.33 Cash FlowGBX 11.07 per share Price / Cash Flow14.90 Book ValueGBX (15.80) per share Price / Book-10.44Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees72 Outstanding Shares34,870,100Market Cap£57.54 million Next Earnings DateN/A OptionableNot Optionable LSE:GDR Rates by TradingView Receive GDR News and Ratings via Email Sign-up to receive the latest news and ratings for GDR and its competitors with MarketBeat's FREE daily newsletter. Genedrive (LON:GDR) Frequently Asked Questions How has Genedrive's stock been impacted by COVID-19 (Coronavirus)? Genedrive's stock was trading at GBX 9 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GDR stock has increased by 1,733.3% and is now trading at GBX 165. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Genedrive? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genedrive in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genedrive. How were Genedrive's earnings last quarter? Genedrive PLC (LON:GDR) posted its earnings results on Tuesday, February, 4th. The company reported ($8.90) earnings per share (EPS) for the quarter. View Genedrive's earnings history. Has Genedrive been receiving favorable news coverage? Press coverage about GDR stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genedrive earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutGenedrive. Who are some of Genedrive's key competitors? Some companies that are related to Genedrive include Akumin (AKU), Exagen (XGN), Yourgene Health (YGEN), Senseonics (SENS), Palatin Technologies (PTN), MaxCyte (MXCT), Oncosil Medical (OSL), Lexagene (LXG), Oncimmune (ONC), SQI Diagnostics (SQD), BARD1 Life Sciences (BD1), Sernova (SVA), GeneNews (GEN), Deepmatter Group (DMTR) and Imagion Biosys (IBX). View all competitors. What other stocks do shareholders of Genedrive own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genedrive investors own include NVIDIA (NVDA), Asbury Automotive Group (ABG), Allena Pharmaceuticals (ALNA), Amphenol (APH), Benchmark Electronics (BHE), Bank of New York Mellon (BK), Berkeley Energia (BKY), Brady (BRC), BorgWarner (BWA) and Chuy's (CHUY). Who are Genedrive's key executives? Genedrive's management team includes the following people: Mr. David Budd, CEO & Director (Age 51)Mr. Matthew J. Fowler, CFO, Company Sec. & Director (Age 44) What is Genedrive's stock symbol? Genedrive trades on the London Stock Exchange (LON) under the ticker symbol "GDR." How do I buy shares of Genedrive? Shares of GDR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Genedrive's stock price today? One share of GDR stock can currently be purchased for approximately GBX 165. How big of a company is Genedrive? Genedrive has a market capitalization of £57.54 million and generates £1.50 million in revenue each year. Genedrive employs 72 workers across the globe. What is Genedrive's official website? The official website for Genedrive is www.genedriveplc.com. How can I contact Genedrive? Genedrive's mailing address is 48 Grafton Street, MANCHESTER, M13 9XX, United Kingdom. The company can be reached via phone at +44-161-9890245. This page was last updated on 5/24/2020 by MarketBeat.com Staff
